Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in RAS-Mutant Lung Cancer
- PMID: 32216949
- DOI: 10.1016/j.jtho.2020.01.004
Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in RAS-Mutant Lung Cancer
Comment in
-
LKB1ness Dictates ERK Inhibitors Response in NSCLC.J Thorac Oncol. 2020 Apr;15(4):e59. doi: 10.1016/j.jtho.2020.02.006. J Thorac Oncol. 2020. PMID: 32216950 No abstract available.
Comment on
-
LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors.J Thorac Oncol. 2020 Mar;15(3):360-370. doi: 10.1016/j.jtho.2019.10.009. Epub 2019 Oct 18. J Thorac Oncol. 2020. PMID: 31634668
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous